%0 Journal Article
%T Novel Liver Injury Phenotypes and Outcomes in Clinical Trial Participants with Pulmonary Hypertension.
%A Scott JV
%A Moutchia J
%A McClelland RL
%A Al-Naamani N
%A Weinberg E
%A Palevsky HI
%A Minhas J
%A Appleby DK
%A Smith A
%A Pugliese SC
%A Ventetuolo CE
%A Kawut SM
%J Am J Respir Crit Care Med
%V 0
%N 0
%D 2024 May 31
%M 38820270
%F 30.528
%R 10.1164/rccm.202311-2196OC
%X <B>BACKGROUND: </B>Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) cause right ventricular dysfunction which can impact other solid organs. However, the profiles and consequences of hepatic injury due to PAH and CTEPH have not been well-studied.<BR><B>OBJECTIVE: </B>We aimed to identify underlying patterns of liver injury in a cohort of PAH and CTEPH patients enrolled in 15 randomized clinical trials conducted between 1998 and 2014.<BR><B>METHODS: </B>We used unsupervised machine learning to identify liver injury clusters in 13 trials and validated the findings in two additional trials. We then determined whether these liver injury clusters were associated with clinical outcomes or treatment effect heterogeneity.<BR><B>RESULTS: </B>Our training dataset included 4,219 patients and our validation dataset included 1,756 patients with serum total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and albumin data. Using k-means clustering, we identified phenotypes with no liver injury, hepatocellular injury, cholestatic injury, and combined injury patterns. Patients in the cholestatic injury liver cluster had the shortest time to clinical worsening and the highest risk of mortality. The cholestatic injury group also experienced the greatest placebo-corrected treatment effect on six-minute walk distance. Randomization to the experimental arm transitioned patients to a healthier liver status.<BR><B>CONCLUSIONS: </B>Liver injury was associated with adverse outcomes in patients with PAH and CTEPH. Randomization to active treatment had beneficial effects on liver health compared to placebo. The role of liver disease (often subclinical) in determining outcomes warrants prospective studies.